Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer
Highlights • Primary platinum-free interval correlates with PFS and OS across multiple therapies. • BRCA testing averaged 36% in this community-based sample. • Presence of a BRCA mutation trends toward delayed primary recurrence. • Data provide benchmarks for design and interpretation of trials in r...
Gespeichert in:
| Veröffentlicht in: | Gynecologic oncology 2017-07, Vol.146 (1), p.58-63 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 63 |
|---|---|
| container_issue | 1 |
| container_start_page | 58 |
| container_title | Gynecologic oncology |
| container_volume | 146 |
| creator | Bookman, Michael A Tyczynski, Jerzy E Espirito, Janet L Wilson, Thomas W Fernandes, Ancilla W |
| description | Highlights • Primary platinum-free interval correlates with PFS and OS across multiple therapies. • BRCA testing averaged 36% in this community-based sample. • Presence of a BRCA mutation trends toward delayed primary recurrence. • Data provide benchmarks for design and interpretation of trials in recurrent disease. |
| doi_str_mv | 10.1016/j.ygyno.2017.04.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1893551255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0090825817307928</els_id><sourcerecordid>1893551255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-f5d4dd28572c9ab0ed68d3066fcbc7bb02297f1758535b467078e5e3853db22d3</originalsourceid><addsrcrecordid>eNqFksuO1DAQRS0EYpqBL0BCXrJJpuzEibMAaabFY6SRkHisLceugJvEaWynUf8Bn40z3bBgw6ps61yX6t4i5DmDkgFrrnbl8evRzyUH1pZQl8DYA7Jh0ImikaJ7SDYAHRSSC3lBnsS4A4AKGH9MLrisRd2IbkN-3U57bRKdB7oPbtLhSPejTs4vUzEEROp8wnDQI9Xe0puP22t2xem0pMzMnsZcl0jzKQXUaUKf7sG4hINbVc7TfUbze6Q_XfpGA5olhJWbDzo47anR3mB4Sh4Neoz47FwvyZe3bz5v3xd3H97dbq_vClOzOhWDsLW1XIqWm073gLaRtoKmGUxv2r4Hzrt2YK2QohJ93bTQShRY5avtObfVJXl5-ncf5h8LxqQmFw2Oo_Y4L1Ex2VVCMC5ERqsTasIcY8BBnS1SDNQagdqp-wjUGoGCWuUIsurFucHST2j_av54noFXJwDzmAeHQUWTDTJoXTYnKTu7_zR4_Y_ejM47o8fveMS4m5fgs4OKqcgVqE_rFqxLwNoK2o7L6jc0zq_H</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1893551255</pqid></control><display><type>article</type><title>Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Bookman, Michael A ; Tyczynski, Jerzy E ; Espirito, Janet L ; Wilson, Thomas W ; Fernandes, Ancilla W</creator><creatorcontrib>Bookman, Michael A ; Tyczynski, Jerzy E ; Espirito, Janet L ; Wilson, Thomas W ; Fernandes, Ancilla W</creatorcontrib><description>Highlights • Primary platinum-free interval correlates with PFS and OS across multiple therapies. • BRCA testing averaged 36% in this community-based sample. • Presence of a BRCA mutation trends toward delayed primary recurrence. • Data provide benchmarks for design and interpretation of trials in recurrent disease.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2017.04.011</identifier><identifier>PMID: 28454659</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; BRCA1/2 ; Carcinoma, Ovarian Epithelial ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Germ-Line Mutation ; Hematology, Oncology and Palliative Medicine ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local - genetics ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - therapy ; Neoplasm Staging ; Neoplasms, Glandular and Epithelial - drug therapy ; Neoplasms, Glandular and Epithelial - genetics ; Neoplasms, Glandular and Epithelial - mortality ; Obstetrics and Gynecology ; Organoplatinum Compounds - administration & dosage ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - mortality ; PARP ; Platinum-free interval ; Retrospective Studies ; United States - epidemiology ; Young Adult</subject><ispartof>Gynecologic oncology, 2017-07, Vol.146 (1), p.58-63</ispartof><rights>2017 Elsevier Inc.</rights><rights>Copyright © 2017 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-f5d4dd28572c9ab0ed68d3066fcbc7bb02297f1758535b467078e5e3853db22d3</citedby><cites>FETCH-LOGICAL-c414t-f5d4dd28572c9ab0ed68d3066fcbc7bb02297f1758535b467078e5e3853db22d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ygyno.2017.04.011$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28454659$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bookman, Michael A</creatorcontrib><creatorcontrib>Tyczynski, Jerzy E</creatorcontrib><creatorcontrib>Espirito, Janet L</creatorcontrib><creatorcontrib>Wilson, Thomas W</creatorcontrib><creatorcontrib>Fernandes, Ancilla W</creatorcontrib><title>Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Highlights • Primary platinum-free interval correlates with PFS and OS across multiple therapies. • BRCA testing averaged 36% in this community-based sample. • Presence of a BRCA mutation trends toward delayed primary recurrence. • Data provide benchmarks for design and interpretation of trials in recurrent disease.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>BRCA1/2</subject><subject>Carcinoma, Ovarian Epithelial</subject><subject>Female</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Germ-Line Mutation</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Glandular and Epithelial - drug therapy</subject><subject>Neoplasms, Glandular and Epithelial - genetics</subject><subject>Neoplasms, Glandular and Epithelial - mortality</subject><subject>Obstetrics and Gynecology</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - mortality</subject><subject>PARP</subject><subject>Platinum-free interval</subject><subject>Retrospective Studies</subject><subject>United States - epidemiology</subject><subject>Young Adult</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksuO1DAQRS0EYpqBL0BCXrJJpuzEibMAaabFY6SRkHisLceugJvEaWynUf8Bn40z3bBgw6ps61yX6t4i5DmDkgFrrnbl8evRzyUH1pZQl8DYA7Jh0ImikaJ7SDYAHRSSC3lBnsS4A4AKGH9MLrisRd2IbkN-3U57bRKdB7oPbtLhSPejTs4vUzEEROp8wnDQI9Xe0puP22t2xem0pMzMnsZcl0jzKQXUaUKf7sG4hINbVc7TfUbze6Q_XfpGA5olhJWbDzo47anR3mB4Sh4Neoz47FwvyZe3bz5v3xd3H97dbq_vClOzOhWDsLW1XIqWm073gLaRtoKmGUxv2r4Hzrt2YK2QohJ93bTQShRY5avtObfVJXl5-ncf5h8LxqQmFw2Oo_Y4L1Ex2VVCMC5ERqsTasIcY8BBnS1SDNQagdqp-wjUGoGCWuUIsurFucHST2j_av54noFXJwDzmAeHQUWTDTJoXTYnKTu7_zR4_Y_ejM47o8fveMS4m5fgs4OKqcgVqE_rFqxLwNoK2o7L6jc0zq_H</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Bookman, Michael A</creator><creator>Tyczynski, Jerzy E</creator><creator>Espirito, Janet L</creator><creator>Wilson, Thomas W</creator><creator>Fernandes, Ancilla W</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170701</creationdate><title>Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer</title><author>Bookman, Michael A ; Tyczynski, Jerzy E ; Espirito, Janet L ; Wilson, Thomas W ; Fernandes, Ancilla W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-f5d4dd28572c9ab0ed68d3066fcbc7bb02297f1758535b467078e5e3853db22d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>BRCA1/2</topic><topic>Carcinoma, Ovarian Epithelial</topic><topic>Female</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Germ-Line Mutation</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Glandular and Epithelial - drug therapy</topic><topic>Neoplasms, Glandular and Epithelial - genetics</topic><topic>Neoplasms, Glandular and Epithelial - mortality</topic><topic>Obstetrics and Gynecology</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - mortality</topic><topic>PARP</topic><topic>Platinum-free interval</topic><topic>Retrospective Studies</topic><topic>United States - epidemiology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bookman, Michael A</creatorcontrib><creatorcontrib>Tyczynski, Jerzy E</creatorcontrib><creatorcontrib>Espirito, Janet L</creatorcontrib><creatorcontrib>Wilson, Thomas W</creatorcontrib><creatorcontrib>Fernandes, Ancilla W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bookman, Michael A</au><au>Tyczynski, Jerzy E</au><au>Espirito, Janet L</au><au>Wilson, Thomas W</au><au>Fernandes, Ancilla W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>146</volume><issue>1</issue><spage>58</spage><epage>63</epage><pages>58-63</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Highlights • Primary platinum-free interval correlates with PFS and OS across multiple therapies. • BRCA testing averaged 36% in this community-based sample. • Presence of a BRCA mutation trends toward delayed primary recurrence. • Data provide benchmarks for design and interpretation of trials in recurrent disease.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28454659</pmid><doi>10.1016/j.ygyno.2017.04.011</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0090-8258 |
| ispartof | Gynecologic oncology, 2017-07, Vol.146 (1), p.58-63 |
| issn | 0090-8258 1095-6859 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1893551255 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage BRCA1/2 Carcinoma, Ovarian Epithelial Female Genes, BRCA1 Genes, BRCA2 Germ-Line Mutation Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Middle Aged Neoplasm Grading Neoplasm Recurrence, Local - genetics Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - therapy Neoplasm Staging Neoplasms, Glandular and Epithelial - drug therapy Neoplasms, Glandular and Epithelial - genetics Neoplasms, Glandular and Epithelial - mortality Obstetrics and Gynecology Organoplatinum Compounds - administration & dosage Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - mortality PARP Platinum-free interval Retrospective Studies United States - epidemiology Young Adult |
| title | Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A09%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20primary%20platinum-free%20interval%20and%20BRCA1/2%20mutation%20status%20on%20treatment%20and%20survival%20in%20patients%20with%20recurrent%20ovarian%20cancer&rft.jtitle=Gynecologic%20oncology&rft.au=Bookman,%20Michael%20A&rft.date=2017-07-01&rft.volume=146&rft.issue=1&rft.spage=58&rft.epage=63&rft.pages=58-63&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2017.04.011&rft_dat=%3Cproquest_cross%3E1893551255%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1893551255&rft_id=info:pmid/28454659&rft_els_id=1_s2_0_S0090825817307928&rfr_iscdi=true |